{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI were not available due to censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI were not available due to censoring.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI were not available due to censoring.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"94"}],"units":"Participants"}],"description":"OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"MEDIAN","populationDescription":"All randomized participants were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Up to approximately 8.9 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}